---
title: "Ami Fadia Reiterates Buy on Harmony Biosciences, Raises Price Target to $45 on Solid Wakix Demand and Reaffirmed 2026 Revenue Guidance"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285588735.md"
description: "Needham analyst Ami Fadia has reiterated a Buy rating on Harmony Biosciences Holdings, raising the price target to $45 due to strong demand for Wakix and reaffirmed 2026 revenue guidance of $1.0 billion to $1.04 billion. Despite a one-time spike in R&D spending affecting Q1 2026 earnings, lower administrative costs and healthy core demand for Wakix support the positive outlook. Oppenheimer also maintains a Buy rating with a $72 price target."
datetime: "2026-05-07T16:45:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285588735.md)
  - [en](https://longbridge.com/en/news/285588735.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285588735.md)
---

# Ami Fadia Reiterates Buy on Harmony Biosciences, Raises Price Target to $45 on Solid Wakix Demand and Reaffirmed 2026 Revenue Guidance

Needham analyst Ami Fadia maintained a Buy rating on Harmony Biosciences Holdings today and set a price target of $45.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Ami Fadia has given his Buy rating due to a combination of factors tied to Harmony Biosciences’ underlying business momentum and outlook. While first-quarter 2026 earnings per share were below expectations because of a one-time spike in research and development spending and slightly softer revenue, these were partly balanced by lower selling, general, and administrative costs.

The R&D overshoot largely reflected upfront licensing payments, which impact earnings but are not indicative of recurring cost pressure, and core demand for Wakix remained healthy, with more patients on therapy at quarter end despite seasonal access challenges. Importantly, management reaffirmed its 2026 net revenue guidance of $1.0 billion to $1.04 billion, and Fadia modestly lifted her price target from $44 to $45, signaling confidence in the company’s growth trajectory and long-term value.

In another report released on April 22, Oppenheimer also maintained a Buy rating on the stock with a $72.00 price target.

### Related Stocks

- [HRMY.US](https://longbridge.com/en/quote/HRMY.US.md)
- [OPY.US](https://longbridge.com/en/quote/OPY.US.md)

## Related News & Research

- [Assessing Harmony Biosciences (HRMY) Valuation After Softer Earnings But Stronger Free Cash Flow](https://longbridge.com/en/news/286683639.md)
- [A beaten-down biotech just lost a meaningful backer — should you care?](https://longbridge.com/en/news/286971136.md)
- [Do Wall Street Analysts Like Equity Residential Stock?](https://longbridge.com/en/news/286806057.md)
- [This Analyst Just Sent Mobileye Stock Down. Here's Why.](https://longbridge.com/en/news/286817003.md)
- [Core Scientific Is Firing on All Cylinders as Analysts Approve Its Expansion Plans](https://longbridge.com/en/news/286808678.md)